Key takeaways
Rinvoq (upadacitinib) and Actemra (tocilizumab) are both medications used to treat inflammatory conditions like rheumatoid arthritis (RA). However, they belong to different medication classes. Rinvoq is a Janus kinase (JAK) inhibitor, while Actemra is an interleukin-6 (IL-6) receptor antagonist. Rinvoq is taken orally, either as an extended-release tablet or an oral solution, and is typically dosed once daily. In contrast, Actemra is administered via injection, either intravenously or subcutaneously, with dosing intervals ranging from weekly to monthly. Rinvoq is available only as a brand-name medication, whereas Actemra has a biosimilar option called Tofidence. Common side effects of Rinvoq include a higher risk of infections, acne, and nausea, while Actemra can cause upper respiratory tract infections, headaches, and high blood pressure. Both medications can increase the risk of infections due to their immunosuppressive effects, but they have different interactions and precautions. For example, Rinvoq should not be taken with grapefruit, and Actemra requires careful monitoring of liver function.
